IL-33 deficiency protects mice from DSS-induced experimental colitis by suppressing ILC2 and Th17 cell responses
- PDF / 5,369,633 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 63 Downloads / 151 Views
Inflammation Research
ORIGINAL RESEARCH PAPER
IL‑33 deficiency protects mice from DSS‑induced experimental colitis by suppressing ILC2 and Th17 cell responses Xueying Qiu1 · Chang Qi1 · Xiaoxiao Li1 · Dai Fang2 · Min Fang1 Received: 24 September 2019 / Revised: 21 June 2020 / Accepted: 22 July 2020 © Springer Nature Switzerland AG 2020
Abstract Background Recently, IL-33-driven ILC2 response has been shown to participate in a variety of diseases. However, IL33-driven ILC2 immunity has not been extensively characterized in the context of colitis yet. Materials and subjects The RAG-2- and IL-33-deficient mice were used to investigate the role and underlying mechanisms of IL-33-driven ILC2 response in the DSS-induced experimental colitis. Body weight, length of colon, and histological analysis were monitored to evaluate the severity of colitis. Proportions of immune cells were examined by flow cytometry. Levels of cytokines were analyzed by ELISA and q-PCR. Results Administration of exogenous IL-33 aggravated the DSS-induced colitis, which revealed that IL-33 promoted the generation of ILC2 cells to mediate the inflammation of colon. Consistently, this effect was confirmed in RAG-2-deficient mice without T, B cells. Furthermore, IL-33-deficient mice were used to examine the role of endogenous IL-33 on the pathogenesis of DSS-induced colitis. Interestingly, lack of endogenous IL-33 protected the mice from the DSS-induced colitis. The protective effect is associated with impairments of development of ILC2 as well as Th17 cells. Analysis of their cytokine production profiles revealed that IL-33 deficiency resulted in the reduction of cytokines IL-6 and IL-1β as well as IL-10. These results suggest that IL-33/ILC2 axis is a potential therapeutic target for human colitis. Conclusion Our findings demonstrate that IL-33 deficiency protects mice from DSS-induced colitis. The protective effect is associated with impairments of ILC2 and Th17 cell development as well as reduction of inflammatory cytokines IL-6 and IL-1β. Keywords Interleukin (IL)-33 · Group 2 innate lymphoid cells · DSS (dextran sulfate sodium) · Th17 cells · Colitis Abbreviations IBD Human inflammatory bowel disease ILC2 Group 2 innate lymphoid cells DSS Dextran sulfate sodium IL-33 Interleukin (IL)-33 DCs Dendritic cells Tfh cells Follicular T helper cells Responsible Editor: John Di Battista. Xueying Qiu and Chang Qi contributed equally to this work. * Min Fang [email protected] 1
Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13# Hangkong Road, Wuhan 430030, China
Department of Biostatistics, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA
2
Tregs Regulatory T cells Q-PCR Quantitative real-time PCR
Introduction The incidence of human inflammatory bowel disease (IBD) has increased markedly in recent decades; thus, the identification of potential therapeutic targets is of vital importance [1]. Interleukin-33 (IL-33) is a chromatin-ass
Data Loading...
